Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SOBR | Sobr Safe | $2.43 | $1.13 | 87.27% | 37.3M | $2.0M | $1.27$14.50 |
| INDP | Indaptus Therapeutics | $3.06 | $1.11 | 56.92% | 15.3M | $3.4M | $1.65$47.60 |
| DVAX | Dynavax Technologies | $15.41 | $4.28 | 38.47% | 8.1M | $1.3B | $9.20$15.49 |
| IZM | Iczoom Group | $2.33 | $0.53 | 29.44% | 212.4K | $22M | $0.87$2.74 |
| AFJK | Aimei Health Technology | $56.69 | $12.68 | 28.81% | 49K | $269M | $6.75$98.15 |
| EUDA | Euda Health | $2.47 | $0.55 | 28.64% | 722.3K | $73M | $1.03$4.70 |
| DRMA | Dermata Therapeutics | $2.48 | $0.44 | 21.57% | 16.8M | $2.1M | $1.97$23.70 |
| RPTX | Repare Therapeutics | $2.61 | $0.44 | 20.05% | 10.3M | $94M | $0.89$2.64 |
| TNMG | Tnl Mediagene | $3.24 | $0.49 | 17.82% | 7.3M | $114M | $2.40$223.51 |
| AGIO | Agios Pharmaceuticals | $28.48 | $3.89 | 15.81% | 1.5M | $1.4B | $22.24$46.00 |
Related Articles
Featured Article
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
George Budwell, PhD|Aug 16, 2023
This small-cap biotech stock holds enormous growth potential.
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
Will Valneva and Dynavax Score With Their Late-to-the-Party COVID Vaccine?
Keith Speights and Brian Orelli, PhD|Oct 29, 2021
There's still a sizable market opportunity, especially in developing nations.
Advertisement
How Will Valneva's COVID Vaccine Setback Impact Dynavax?
Keith Speights and Brian Orelli, PhD|Sep 25, 2021
It's definitely not a showstopper for the biotech or its CpG 1018 adjuvant.
2 Biotech Stocks ARK Invest Bought in June
Cory Renauer|Jun 7, 2021
Should you follow Cathie Wood's latest genomic revolution investments?
How Dynavax Demolished Expectations With Its Q1 Results
Keith Speights|May 7, 2021
The company's hepatitis B vaccine wasn't its key growth driver.
Sell-Off? Correction? These 3 Stocks Are Already 40% Off Their Highs
Rick Munarriz|Mar 23, 2021
In a little more than a month, these three stocks have surrendered between 42% and 47% of their value. This correction could use a correction.
Dynavax's Q4 Results Show It's Not Just About Heplisav-B Anymore
Keith Speights|Feb 26, 2021
The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.
2 Great Stocks Under $10 a Share
Dave Kovaleski|Jan 28, 2021
One is making a COVID-19 vaccine; the other is a fintech.
4 Reasons Agios' Oncology Deal Should Please Investors
Cory Renauer|Dec 22, 2020
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
